Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DAVID HU who wrote (4)	6/22/1996 2:08:00 AM
From: Anthony Tran	of 496

David, I recently red in BioCentury that the Advisory Board recommended the approval of Gliadel for a secondary use in the treatment of brain cancer and not for first line use. Although FDA is not required to follow the Advisory recommendation however the opposite is unprecedented. This means pretty sure deal that Glfd will have the drug approve by year end for limited use and therefore small market for brain surgery. This is on paper, and Glfd could not go out and advertised Gliadel as first therapy; however the doctor is free to use this drug as appropriate. This mean in practical that sale of Gliadel may not be significantly affected by the limited approval. I still think this company has a very bright future ahead since this is not a typical high risk biotech company. What does it mean? Glfd does not try to chase unknown proteins for therapeutic use they develop a special drug delivery system "wafer" for specific local drug delivery and therefore reduce toxicity. They will set up clinial using this technology with 4 Rhone poulenc's drugs (ie taxotere). This type of approach is the least risky and some other companies who are successfull with this strategy are Inhale and Depotech.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next